The agreement grants Echo exclusive rights of first negotiation to all dermatology product and transdermal drug delivery technology opportunities identified or acquired by Cato BioVentures.
Patrick Mooney, Echo’s chairman and CEO, said: “This agreement expands our long-standing strategic relationship with Cato BioVentures and Cato Research and enables us to leverage their deep industry access to a wide range of business development opportunities in our core focus areas.”